Roche: Maintaining Leadership is difficult: nearterm pipeline outlook

We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin lymphoma to breakthroughs for Duchene muscular dystrophy and find unique assets, but also successful competition